Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal mannitol crossover study in chronic rhinosinusitis and persistent allergic rhinitis
ACTRN12605000473662Phase 3Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Jun 2005
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bronchitol in chronic rhinosinusitis (CRS) and allergic rhinitis (AR) (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Nasal mucociliary clearance rate. Started Jun 2005; status: completed.
02
Drugs
Bronchitol
03
Conditions
chronic rhinosinusitis (CRS)allergic rhinitis (AR)
Beyond the preview
Go deeper on ACTRN12605000473662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000473662.